{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-24-000021","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.556208+00:00","generated_at":"2026-06-02T23:57:53.789326+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alnylam Q1 net product rev $365M (+32% YoY); net loss narrows to $0.52/share","bullets":["Net product revenue $365M, up 32% YoY; TTR franchise $264M (+29%), Rare $101M (+40%).","GAAP net loss $65.9M ($0.52 per share) vs $174.1M ($1.40) in Q1 2023.","2024 guidance reiterated: combined net product revenue $1.4B–$1.5B.","Zilebesiran: positive KARDIA-2 results; KARDIA-3 initiated, triggering $65M Roche milestone.","HELIOS-B Phase 3 topline results for vutrisiran on track for late June/early July."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-24-000021","json":"https://secwatch.observer/filing/0001178670-24-000021.json","markdown":"https://secwatch.observer/filing/0001178670-24-000021.md","text":"https://secwatch.observer/filing/0001178670-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/0001178670-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/alny-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:57:53.789326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"078cf89e1d112474bfc57b6cc68ad9cb344bb3d8","claim":"ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended March 31, 2024 results: revenue $365 million, net income GAAP Net loss $65,935 (in thousands), EPS GAAP Net loss per common share - basic and diluted $0.52. Guidance reaffirmed.","evidence_excerpt":"Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2024 Global Net Product Revenues of $365 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867024000021/0001178670-24-000021-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$365 million"},{"label":"Net income","value":"GAAP Net loss $65,935 (in thousands)"},{"label":"EPS","value":"GAAP Net loss per common share - basic and diluted $0.52"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}